医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Nanox Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

2020年08月26日 AM01:14
このエントリーをはてなブックマークに追加


 

NEVE ILAN, Israel

NANO-X IMAGING LTD (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today the closing of its initial public offering of 10,555,556 ordinary shares, which includes the full exercise of the underwriters’ option to purchase 1,376,812 additional ordinary shares at a public offering price of US$18.00 per share. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nanox, were US$190.0 million. All of the shares were offered by Nanox. The shares began trading on the Nasdaq Global Market under the ticker symbol “NNOX” on August 21, 2020.

Cantor Fitzgerald & Co., Oppenheimer & Co. Inc., Berenberg and CIBC Capital Markets acted as joint book-runners. National Securities Corporation acted as co-manager for the offering.

A registration statement, including a prospectus, on Form F-1 relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. The offerings were made only by means of a prospectus. Copies of the final prospectus may be obtained by contacting: Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com, Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, New York 10004, by telephone at (212) 667-8055, or by email at EquityProspectus@opco.com, Berenberg Capital Markets, LLC, Attention: Equity Capital Markets, 1251 Avenue of the Americas, 53rd Floor, New York, NY 10020, telephone: (646) 949-9000, or CIBC Capital Markets, 425 Lexington Avenue, 5th floor, New York, NY, by telephone at (800) 282-0822, or by email at useprospectus@cibc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200825005756/en/

CONTACT

IR contacts:

Bob Yedid

LifeSci Advisors, LLC

646-597-6989

bob@lifesciadvisors.com

Itzhak Maayan, CFO at Nanox

IR@nanox.vision

Media Contact:

Alona Stein

ReBlonde for Nanox

alona@reblonde.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 首尔伟傲世Violeds技术解决方案有效防止病毒在公共和多功能场所传播
  • Sengenics Launches SEROMAX, an At-Home, Antibody Sample Collection Kit That Will Revolutionise Patient Recruitment and Monitoring in Clinical Trials
  • UAEの20by2020イニシアチブがカンボジアの村民数千人の生活を変える水資源ソリューションを導入
  • 阿联酋的20by2020计划为柬埔寨村庄数千居民带来挽救生命的水资源解决方案
  • LianBio Announces $310 Million Crossover Financing